TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05560425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Koru Mindfulness (KM) Training
Description: The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigating College (NC) Training
Description: With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
Study: NCT06347731

Intervention type: DEVICE
Group type: OTHER
Intervention: Proton Radiation Therapy
Description: All enrolled participants will be treated with Proton radiation therapy using the medical device Varian ProBeam360° Proton Therapy System. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up which is 3 months after treatment completion and long-term follow-up which is 5 years after treatment completion.
Study: NCT05881018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycaemic index
Description: Diet will be supplemented with a drink containing a low glycaemic index carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycaemic index
Description: Diet will be supplemented with a drink containing a low glycaemic index carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycaemic index
Description: Diet will be supplemented with a drink containing a high glycaemic index carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycaemic index
Description: Diet will be supplemented with a drink containing a high glycaemic index carbohydrate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will include physical activity units

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will include physical activity units
Study: NCT06125834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1)
Description: Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
Study: NCT05841732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Education; Pain Medication, imaging, referrals to other health services, other health care appointments

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Education; Pain Medication, imaging, referrals to other health services, other health care appointments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyBack Program
Description: A tailored exercise and behavioural change program
Study: NCT06145191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Prophylactic topical application (1x) of tranexamic acid (100mg, 2ml, room temperature) before sampling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Prophylactic topical application (1x) of adrenaline (1:10.000, 2ml, room temperature) before sampling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
Study: NCT05397834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT DISKUS
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT05428930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKDB-501B
Description: Intramuscular injection CKDB-501B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®50U
Description: Intramuscular injection Botox®50U
Study: NCT06067061

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab + RP1
Description: Patients will be treated in a window period (ie 3 treatment cycles). After evaluation, patients that had no increase in ctDNA after 3 cycles (see Definition of ctDNA status) will continue on the same treatment (intratumoral injections of RP1 in combination with Atezolizumab) for a total of 10 treatment cycles prior to surgery.
Study: NCT04133506

Intervention type: DRUG
Intervention: Aspirin 300mg
Description: see earlier (only half of healthy volunteers receive aspirin)
Study: NCT06596447

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: While most patients with obsessive compulsive disorder (OCD) eventually respond to treatment with medication and/or behavioral therapy, a small minority do not improve following all conventional treatments. Obsessive-compulsive disorder (OCD) can sometimes be difficult to treat with medication and psychotherapy. For these patients, in this study, we employ deep brain stimulation (DBS), an advanced surgical treatment that uses electrical impulses.
Study: NCT06132269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AKK formula prebiotic sachet
Description: 5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: 5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks.
Study: NCT06610786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: foldable capsular scleral buckling
Description: Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy
Description: Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
Study: NCT06204341

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HYPOPRIME treatment
Description: Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
Study: NCT05502367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-2280 Vaginal Tablet/Insert
Description: Vaginal Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-2280 Vaginal Tablet/Insert
Description: Vaginal Tablet
Study: NCT05605678

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06132451

Intervention type: OTHER
Group type: OTHER
Intervention: Postponement of antihypertensive treatment
Description: Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
Study: NCT05891431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Untire mobile app
Description: The Untire app is an mHealth intervention (digitally delivered using a smartphone app).~Untire offers a comprehensive program to help you understand cancer fatigue and gives a physical activity program, stress reduction exercises and tips to manage your energy level.
Study: NCT06334393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: 0.45mL (milliliter), Day 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: 0.45mL (milliliter), Day 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: 0.45mL (milliliter), Day 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: 0.45mL (milliliter), Day 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: 0.45mL (milliliter), Day 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018®
Description: CpG 1018® will be investigated in combination with VLA1601 Low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3M-052-AF will be investigated in combination with VLA1601 Low dose
Study: NCT06362746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-immunogenic recombinant staphylokinase
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Study: NCT06247995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB is a radioligand therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB is a radioligand therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB is a radioligand therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB is a radioligand therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.
Study: NCT04610346

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Persons with Aphasia Training Dogs Program
Description: Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Persons with Aphasia Training Dogs Program
Description: Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
Study: NCT05499832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
Study: NCT05539027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
Description: patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acids (BCAA), enriched solution (Aminoleban)
Description: patients will receive BCAA enriched solution (Aminoleban)
Study: NCT05930678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ventilation with face mask
Description: During the period of apnea (in general anesthesia), the patient did not help with face mask

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with face mask
Description: During the pperiod of apnea (in general anesthesia), the patient did help with face mask
Study: NCT06285591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri Tablets
Description: Lactobacillus Reuteri lozenges (NOW Foods, Sweden) contained no less than 2×10\^8 CFU viable cells of Lactobacillus Reuteri as the active ingredient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-containing tablets
Description: Starch preparations that look and taste like Lactobacillus Reuteri

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
Study: NCT06589531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: During TIPS operation, shunt diameter or diameter of covered stent
Description: Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.~Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore \&amp;amp; Associates) to create a final 6-mm shunt.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: During TIPS operation, shunt diameter or diameter of covered stent
Description: After successful puncture, in the 8-mm shunt group, a balloon with a diameter of 6 mm was used to expand the shunt, and then an 8-mm covered stent was implanted (Viatorr; WL Gore \&amp; Associates, Inc.).
Study: NCT06596174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation (tSCS)
Description: The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-term Machine-Assisted Ankle Movement Training with tSCS
Description: The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS
Description: The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS).~Each session will last for 30 minutes, conducted three times per week, over a period of four weeks.
Study: NCT06600477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 7.5 mg
Study: NCT05975476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Engagement
Description: Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
Study: NCT06617312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: Targets α4β2 nicotinic acetylcholine receptors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Matched to active drug, cytisinicline
Study: NCT06704555

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: received radiation (dose:18～24Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiselizumab
Description: 200 mg iv day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenous \[IV\] day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg oral days 3-7
Study: NCT06705686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-9bMS
Description: (R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-9bMS
Description: (R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
Study: NCT06706375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using ultrasound for penile nerve block
Description: 30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Penile Block Anesthesia using landmarks
Description: Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
Study: NCT05608434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floreo Virtual Reality application
Description: Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
Study: NCT06381934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard diagnosis and therapy procedures at physician's discretion.